Summary
Thermo Fisher Scientific Inc. (TMO) reported its first-quarter 2024 financial results, showing total revenues of $10.35 billion, a decrease of 3% compared to the prior year's $10.71 billion. This decline was primarily driven by a decrease in Life Sciences Solutions and Analytical Instruments segments, partly offset by stable performance in Specialty Diagnostics and Laboratory Products and Biopharma Services. Despite the revenue dip, operating income saw a modest 6% increase to $1.66 billion, leading to diluted earnings per share (EPS) of $3.46, up from $3.32 in the first quarter of 2023. The company continues to navigate a complex market, with a decrease in COVID-19 related revenue impacting performance. However, management highlights strong productivity improvements and strategic investments as key drivers for future growth. The company also announced its intent to acquire Olink Holding AB for approximately $3.1 billion, expected to close mid-year 2024, which is anticipated to enhance its proteomics capabilities.
Financial Highlights
55 data points| Revenue | $10.35B |
| R&D Expenses | $331.00M |
| SG&A Expenses | $2.18B |
| Operating Expenses | $8.68B |
| Operating Income | $1.66B |
| Interest Expense | $363.00M |
| Net Income | $1.33B |
| EPS (Basic) | $3.47 |
| EPS (Diluted) | $3.46 |
| Shares Outstanding (Basic) | 382.00M |
| Shares Outstanding (Diluted) | 384.00M |
Key Highlights
- 1Total revenues for Q1 2024 were $10.35 billion, a 3% decrease year-over-year, primarily due to lower demand for COVID-19 related products and challenging macroeconomic conditions.
- 2Operating income increased by 6% to $1.66 billion, while diluted EPS rose to $3.46 from $3.32 in the prior year's quarter, indicating improved profitability on a per-share basis.
- 3The Life Sciences Solutions segment experienced a 13% revenue decline, largely due to the moderation of COVID-19 related revenue and lower bioproduction activity.
- 4Thermo Fisher announced a proposed acquisition of Olink Holding AB for approximately $3.1 billion, aiming to expand its proteomics offerings.
- 5Free cash flow generation remained strong, with $908 million in the quarter, significantly up from $277 million in Q1 2023, showcasing robust cash generation capabilities.
- 6The company repurchased $3.0 billion of its common stock in the quarter, reflecting a continued commitment to returning capital to shareholders.
- 7Cash and cash equivalents decreased to $5.5 billion from $8.1 billion at the end of 2023, partly due to significant share repurchases and investments.